secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0000950170-24-031140
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology reports Q4 2023 net loss of $25.6M; CFO Trigilio to depart Mar 29
--------------------------------------------------------------------------------

- Net loss for FY 2023 was $155.1M vs income of $109.2M in 2022; Q4 loss $25.6M.
- Cash and investments $468.3M; runway expected into H2 2026.
- On track to report CLN-619 combo/monotherapy data at a medical meeting in Q2 2024.
- Received FDA IND clearance for CLN-619 in multiple myeloma; exploring CLN-978 in autoimmune diseases.
- CFO Jeff Trigilio to depart effective March 29, 2024, with transition support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/0000950170-24-031140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/cgem-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-031140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer